On March 28, Ge Longhui Pharmaceutical (00013.HK) announced today that the marketing application for new indications of sevotinib for the treatment of locally advanced or metastatic non-small cell lung cancer in adults with locally advanced or metastatic non-small cell lung cancer with the interstitium-epithelial conversion factor (“MET”) exon 14 jump has been accepted by the China Drug Administration (“State Drug Administration”). If approved, the new labeling indication for sevolitinib in China will be extended to cover first-time patients.